Taste and prostate cancer: Preliminary data on a novel patient-reported outcomes
| Autor: | Patrick Cotogno, Oliver Sartor, Elisa Ledet, Charlotte Manogue, Emma M. Ernst, Lydia D. Chow |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Cancer Research
medicine.medical_specialty Taste business.industry media_common.quotation_subject Cancer Appetite medicine.disease Surgery Prostate cancer chemistry.chemical_compound Poor Appetite Oncology chemistry Weight loss Internal medicine medicine Enzalutamide medicine.symptom business Prospective cohort study media_common |
| Zdroj: | Journal of Clinical Oncology. 35:201-201 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2017.35.6_suppl.201 |
| Popis: | 201 Background: Taste alterations are a common yet frequently under-assessed problem in cancer patients. Health-related quality-of-life (HRQOL) instruments for prostate cancer (PCa) patients (pts) do not assess taste despite these hypothetically being related to both appetite and weight loss. Herein we begin to assess taste using a novel instrument evaluating taste alterations with a focus on PCa. Methods: 61 PCa pts treated at Tulane Cancer Center were enrolled in this prospective study. An 18-item questionnaire assessed appetite, taste, smell, and diet. 127 questionnaires were completed (mean 2.1 responses/pt). In a subset of questionnaires, we compared self-reported taste, appetite, and weight loss over a 6-month period. In another subset, we compared taste and appetite to treatments with abiraterone, docetaxel, or enzalutamide. Non-parametric testing was performed. Results: Of the 61 participants with PCa, 18.0% reported poor taste, 17.1% reported poor appetite, and 6.6% reported nausea while eating. When asked to assess to what extent this was a perceived problem, 16.4% rated taste, 13.1% rated nausea, and 16.4% rated appetite as a “moderate” or “big” problem. Men with poor or very poor taste (1 or 2 on a 5 point Likert scale) had a significant association with poor appetite (OR = 7.9, P = 0.0002). There was no direct relationship observed between taste and weight loss. The population with poor appetite was more likely (OR = 21.25, P < 0.0001) to have had ≥ 5% weight loss as compared to those without a poor appetite. Those reporting at least some nausea were also (OR = 8.645, P = 0.0007) more likely to have ≥ 5% weight loss. In the treatment subset, pts on docetaxel at time of survey were 15.17 fold more likely to have poor taste as compared to those on abiraterone (p = 0.0145). Conclusions: We observed that perceived problems with taste were associated with loss of appetite which in turn was associated with weight loss. Weight loss is a known adverse prognostic factor in pts with advanced PCa. Further studies are warranted on this important patient-centric assessment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|